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Introduction
Among the peptide growth factors that are active in breast
glandular cell proliferation, epidermal growth factor (EGF)
is thought to play a role in tumor development. EGF
receptor overexpression has been detected in a variety of
human breast cancer cells [1]. It has been shown to
modulate the growth of mammary gland cells as well as
the proliferation of cultured hormone-sensitive human
breast cancer cells [2]. EGF has potent growth-promoting
effects in mammary epithelium, stimulating DNA synthesis
and cellular proliferation [3]. Much evidence supports the
view that peptide growth factor pathways are intimately
involved in the proliferative response of breast cancer cells
[4,5].
On the other hand, progesterone has important and complex
effects in the mammary gland. In mouse mammary
epithelium it stimulates proliferation, which eventually
culminates in glandular development. Progestins may be
used to treat human breast cancer, mammary fibrosis, and
endometrial carcinoma [6–8]. In breast cancer therapy, for
example, 30–40% of patients whose tumors contain proges-
bp = base pairs; EGF = epidermal growth factor; ERK = extracellular signal-regulated protein kinase; FBS = fetal bovine serum; GAPDH =
glyceraldehyde-3-phosphate dehydrogenase; PCR = polymerase chain reaction; RT = reverse transcriptase; 20×SSC = 3.0 M sodium chloride,
0.3 M sodium citrate buffer.
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Abstract
Introduction: Although the effects of progesterone on cell
cycle progression are well known, its role in spreading and
adhesion of breast cancer cells has not attracted much
attention until recently. Indeed, by controlling cell adhesion
proteins, progesterone may play a direct role in breast cancer
invasion and metastasis. Progesterone has also been shown to
modulate epidermal growth factor (EGF) effects in neoplasia,
although EGF effects on progesterone pathways and targets
are less well understood. In the present study we identify an
effect of EGF on a progesterone target, namely desmoplakin.
Methods: Initially flow cytometry was used to establish the
growing conditions and demonstrate that the T47D breast
cancer cell line was responding to progesterone and EGF in a
classical manner. Differential display RT-PCR was employed to
identify differentially expressed genes affected by progesterone
and EGF. Western and Northern blotting were used to verify
interactions between EGF and progesterone in three breast
cancer cell lines: T47D, MCF-7, and ZR-75.
Results: We found the cell adhesion protein desmoplakin to
be upregulated by progesterone – a process that was
suppressed by EGF. This appears to be a general but not
universal effect in breast cancer cell lines.
Conclusion: Our findings suggest that progesterone and EGF
may play opposing roles in metastasis. They also suggest that
desmoplakin may be a useful biomarker for mechanistic studies
designed to analyze the crosstalk between EGF and
progesterone dependent events. Our work may help to bridge
the fields of metastasis and differentiation, and the mechanisms
of steroid action.
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terone receptors respond to synthetic progestins such as
R5020, suggesting that progestins are as effective in
suppressing tumor growth as the antiestrogen tamoxifen [8].
For these reasons, the effects of progestins and EGF on
the T47D breast cancer cell line were re-examined using
flow cytometry. We found that EGF blocked progestin
suppression of S-phase induction. We then employed
differential display RT-PCR [9] to identify differentially
expressed genes affected by progestin and EGF.
In the study a progestin and EGF responsive gene, desmo-
plakin, was identified. Loss of desmoplakin, a cell adhesion
molecule, has been implicated in breast cancer metastasis.
The expression of desmoplakin was positively regulated by
progestin and negatively regulated by EGF. Furthermore,
EGF reversed progestin upregulation of desmoplakin. This
suggests a role for progestin–EGF interaction not only in
cell cycle progression but also in metastasis. Indeed, the
mitogen EGF may be thought of as having an impact on
progestin-dependent biologic responses.
Methods
EGF, RPMI-1640, L-glutamine, and antibiotics/antimycotics
were purchased from either Sigma (St Louis, MO, USA) or
Invitrogen (Grand Island, NY, USA). Fetal bovine serum
(FBS) was obtained from HyClone (Salt Lake City, UT,
USA). The synthetic progestin R5020 (17,21-dimethyl-
19nor-4,9-pregnadiene-3,20-dione) and [32P]-dCTP were
purchased from Dupont/NEN (Boston, MA, USA). Delta™
RNA Fingerprinting Kit was purchased from Clontech
(Palo Alto, CA, USA). TA cloning kit was purchased from
Invitrogen (San Diego, CA, USA). AmpliCycle™ Sequencing
Kit was purchased from Perkin Elmer (Foster City, CA,
USA). RNA State-60 Kit was purchased from Tel-Test Inc.
(Friendswood, TX, USA). DECA probe template–glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)–mouse
was purchased from Ambion (Austin, TX, USA). Random
primers DNA labeling kit was purchased from Gibco BRL
(Grand Island, NY, USA). Mouse monoclonal antibody to
desmoplakin I and II was purchased from Maine
Biotechnology Services Inc. (Portland, ME, USA).
Antimouse IgG-HRP was purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Actin (C-11),
goat polyclonal antibody, horseradish peroxidase strepta-
vidin, biotinylated antimouse IgG, and biotinylated antigoat
IgG were purchased from Vector Laboratories (Burlingame,
CA, USA). Finally, [33P]-adenosine triphosphate and
enhanced chemiluminescence reagents were purchased
from Amersham Life Science (Arlington Heights, IL).
Cell culture of T47D cells for flow cytometry and RNA
isolation
T47D breast cancer cells were purchased from the
American Type Culture Collection (Rockville, MD, USA).
For RNA isolation and protein lysate, cells were grown in
six-well plates and seeded at 0.5 × 106 cells/well in RPMI-
1640 medium. The medium was supplemented with 10%
FBS, 5 mg/ml insulin, 2 mmol/l L-glutamine, and 1% the
antibiotic/antimycotic mixture.
Cell culture of various breast cancer cell lines for
Western blot analysis
T47D cells were maintained in RPMI-1640 media containing
insulin (5 µg/ml), FBS (10%), and penicillin/streptomycin
(1%) at 37°C in a 5% humidified incubator. ZR-75 and
MCF-7 breast cancer cells were maintained in Dulbecco’s
modified Eagle medium containing FBS (5%) and
penicillin/streptomycin (1%) at 37°C in a 5% humidified
incubator. At 80% of confluency, cells were trypsinized for
5 min at 37°C, washed with phosphate-buffered saline,
and 0.75 × 106 cells were plated in 60 × 15 mm plates in
media containing 5% FBS that was charcoal stripped to
remove endogenous steroids. Cells were then incubated
with vehicle, R5020 (1 × 10–8 mol/l), EGF (1 × 10–8 mol/l),
or R5020 plus EGF for 48 hours.
Flow cytometric analysis
Cell cycle phase distribution was determined by analytical
DNA flow cytometry. Cells were incubated for 48 hours with
100 nmol/l R5020, 10 nmol/l EGF, or 100 nmol/l R5020
plus 10 nmol/l EGF. Treated and control cells were
harvested and adjusted to 5 × 106 cells/ml. Nuclei were
stained with propidium iodine according to the method of
Vindelov and coworkers [10]. A Coulter Electronics EPCS®
Elite Flow Cytometer (Beckman Coulter, Hialeah, FL, USA)
was used to analyze DNA. Normal male lymphocytes served
as working standard. The percentage of cells in the various
phases was calculated by use of multicycle software, as is
standard for our pathology department. Statistical analysis
of the data from the various flow cytometric experiments
was carried out using Microsoft Excel software.
Differential display RT-PCR
Differential display RT-PCR was conducted as described
using the commercially available DeltaTM RNA Finger-
printing Kit. Briefly, 2 µg total RNA was reverse trans-
cribed with 1 µmol/l oligomer used as the 3′ primer. cDNAs
were radiolabeled with [33P]-dATP and amplified by PCR
with arbitrary P and anchor T primers provided in the kit
according to the following program: 1 cycle – 5 min at
94°C, 5 min at 40°C and 5 min at 68°C; 2 cycles – 2 min
at 94°C, 5 min at 40°C, 5 min at 68°C; 25 cycles – 1 min
at 94°C, 1 min at 60°C and 2 min at 68°C; and con-
cluding with one cycle – 7 min at 68°C, for extension. The
reaction products were then separated by electrophoresis
on a 6% nondenatured polyacrylamide gel and identified
by autoradiography. Candidate bands, expressed
differentially in cells treated with progestin, EGF, and
progestin plus EGF, as well as control cells, were excised
from the gel, and then eluted and reamplified by PCR
according to the above PCR program.R241
Sequence analysis
Reamplified PCR products confirmed by Northern blot
were cloned directly into the pCRII vector from the TA
cloning kit according to the manufacturer’s instructions.
Colonies containing the insert were selected for sequencing
by using AmpliCycle™ Sequencing Kit according to the
manufacturer’s instructions. Sequence homology with
known genes was sought by searching the US National
Institutes of Health GenBank database.
RNA isolation and Northern blot analysis
Cells grown to near confluency were incubated for
48 hours with 10 nmol/l R5020 or 10 nmol/l EGF in
medium containing 10% charcoal-treated FBS. Total RNA
was isolated from R5020, EGF, and R5020 plus EGF
treated cells, as well as control cells, by use of RNA State-
60 Kit according to the manufacturer’s instructions.
Total RNA (10 µg) was subjected to electrophoresis in a
1% agarose gel containing formaldehyde, and then
transferred to Optitran® BA-S supported nitrocellulose
membranes with a Turboblotter™ Rapid Downward
Transfer System (Schleicher & Schuell, Keene, NH, USA)
using 20 × SSC (3.0 M sodium chloride, 0.3 M sodium
citrate). Blot hybridization was done in 5 × SSC, 50%
formamide, 2 × Denhardt, 20 mmol/l Na2HPO4, 0.1%
SDS, 10% dextran sulfate, and 100 µg/ml salmon testis
DNA, with the cDNA probe labeled with [32P]-dCTP using
Random Primers DNA Labeling Kit (Gibco BRL, Grand
Island, NY, USA). The hybridization was carried out at
37°C for 24 hours. The blot was then washed twice with
2 × SSC containing 0.2% SDS. The blot was exposed to
X-ray film at –70°C. The autoradiography film of the
Northern blot was scanned with a ScanJet 3C/T Scanner
(Hewlett-Packard, Palo Alto, CA, USA). To compare the
level of desmoplakin induction, the signal intensity of
desmoplakin was divided by the value for the GAPDH.
The control sample was set to 1 and the fold difference for
treatments relative to control was plotted. Statistical
analysis for the fold of induction was determined by t-test.
Western blot analysis
Cells were harvested in cold phosphate-buffered saline
(1×) and lysed by incubating the cell pellet with high-salt
lysis buffer (Tris, pH 7.5 [10 mmol/l], NaCl [400 mmol/l],
EDTA [1 mmol/l], EGTA [1 mmol/l], SDS [1%], Triton
[0.1%], PMSF [0.1 mmol/l], and a protease inhibitor
cocktail [Sigma]) for 10 min in ice. Twenty-five micrograms
of the cellular extract was electrophoresed on a 6.5% or
10% SDS-PAGE gel for desmoplakin and actin, respectively,
and then transferred to nitrocellulose membrane. Western
blot analysis was performed by incubating the membranes
with antibody against desmoplakin I and II or β-actin for
14 hours at 4°C. Secondary antibody was incubated for
1 hour at room temperature, followed by incubation with
horseradish peroxidase streptavidin for 1 hour at room
temperature. Western blot signals were developed by
using enhanced chemiluminescence reagents, and signal
intensity was measured using a Kodak Digital Science 1D
image analysis software station 440 system. To compare
the level of desmoplakin induction among treatments, the
signal intensity of desmoplakin was divided by the value
for the β-actin to normalize for protein load. The vehicle-
treated sample was set to 1 and the fold difference for
treatments relative to vehicle was plotted. Statistical
analysis for the fold of induction was conducted by using
one-way analysis of variance.
Results
The effect of R5020 and epidermal growth factor on
T47D cell cycle progression
To gain insight into EGF–progestin effects, cell cycle
phase distribution was determined by flow cytometry.
T47D cells were treated for 48 hours with 100 nmol/l
R5020, 10 nmol/l EGF, and 100 nmol/l R5020 plus
10 nmol/l EGF, or vehicle. The proportion of cells in S-
phase decreased (P < 0.01 compared with control) when
treated with R5020, and increased when treated with
EGF (P < 0.05 compared with control). The effect of
R5020 was reversed by EGF (Fig. 1), with EGF restoring
the percentage of cells in S phase to values similar to
those of controls. This finding indicated that R5020
inhibited and EGF stimulated T47D cell cycle progression.
Identification and sequence of desmoplakin
In a subsequent series of experiments, RNA samples were
prepared from T47D cells incubated for 48 hours with
R5020, EGF, or R5020 plus EGF (all at 10 nmol/l), as well
as cultured control cells. The RNA was used to synthesize
Available online http://breast-cancer-research.com/content/6/3/R239
Figure 1
The effects of R5020 and epidermal growth factor (EGF) on S-phase
of T47D cells. T47D cells were incubated for 48 hours with 100 nmol/l
R5020, 10 nmol/l EGF, or 100 nmol/l R5020 plus 10 nmol/l EGF.
Controls received vehicle and were allowed to grow for 48 hours.
S-phase was measured by flow cytometry. Each bar is the mean of
three individual experiments. Statistical significance was determined
using t-test. *P < 0.05, **P < 0.01, versus control.the corresponding cDNA, which was subsequently used
for the differential display PCR reaction. For each pair of
primers the differential display was performed twice with
cDNAs derived from two sets of RNAs. The expression of
one band (800 bp fragment) increased in cells incubated
with R5020. It was decreased in cells incubated with
R5020 plus EGF, and with EGF alone (Fig. 2a).
To confirm that this fragment expressed differently, the
800 bp DNA fragment was used as a probe to hybridize a
membrane containing RNAs from T47D cells incubated
with R5020, EGF, R5020 plus EGF (all at 10 nmol/l), and
control cells. The expression of this RNA increased in cells
incubated with R5020. This increase was blocked by
coincubation of EGF with R5020 (Fig. 2b). EGF itself had
at best a modest effect in suppressing expression of this
mRNA. As a control for RNA loading, the membrane was
hybridized with a probe to detect GAPDH transcript. The
mean fold induction results from three independent
experiments are shown in Fig. 2c.
After verification by Northern blot analysis, the 800 bp
fragment of cDNA was subcloned into the pCRII vector
and sequenced. The derived nucleotide sequence was
compared with the GenBank sequences and showed
identity to desmoplakin.
In order to confirm the identified gene, a 1100 bp DNA
fragment of desmoplakin (a gift from Dr Kathleen Green)
was used as a probe to hybridize a RNA membrane.
Similar results to those in Fig. 2 were observed (data not
shown).
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Figure 2
Differential display and Northern blot analysis of R5020 and epidermal growth factor (EGF) regulation of desmoplakin I (DPI) and II (DPII) in T47D
cells. (a) Autoradiography of a representative differential display RT-PCR acrylamide gel. 33P-labeled DNA fragments generated by RT-PCR from
RNAs of control T47D cells (lane 1), 10 nmol/l R5020 treatment (lane 2), 10 nmol/l EGF treatment (lane 3), and 10 nmol/l R5020 plus 10 nmol/l
EGF treatment (lane 4). Each lane contains 5 µl PCR mixture. (A) 1:20 dilution of RT-PCR cDNA. (B) 1:40 dilution of RT-PCR cDNA. The arrow
indicates desmoplakin (DP). Molecular weight standards of 0.65, 0.42, and 0.41 kb are indicated in lane 5. (b) Photograph of a representative
Northern blot analysis of DPI and DPII, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression in T47D cells. Lane 1:
control T47D cells were left untreated for 48 hours. Matched sister colonies of T47D cells received 10nmol/l R5020 (lane 2), 10 nmol/l EGF 
(lane 3), or 10 nmol/l R5020 plus 10 nmol/l EGF (lane 4) for 48 hours. Ten micrograms of total RNA was subjected to Northern blot analysis as
described in the Methods section. (c) The Northern blot films were scanned. The graphs indicate the fold difference of desmoplakin expression
compared with vehicle (set at a value of 1) following measurement of the band intensities. In each independent experiment, the desmoplakin band
for each treatment condition was normalized to the GAPDH signal. The experiment was repeated three times and the mean values from these
experiments ± SEM are reported. Statistical significance was determined using t-test. *P < 0.05, **P < 0.01, versus control.Progestin and epidermal growth factor regulation of
desmoplakin protein in breast cancer cells
To investigate whether the progestin-induced increase in
desmoplakin mRNA expression and inhibition by EGF of
desmoplakin mRNA expression were reflected in protein
expression, and to determine whether this regulation
occurred in other breast cancer cell lines, immunoblot
analyses for desmoplakin protein were performed on
extracts of T47D, ZR-75 and MCF-7 cells. Following
48 hours of exposure of T47D cells to R5020, a clear
increase in desmoplakin I and II protein expression was
found (Fig. 3a). EGF blocked the R5020-dependent
increases in desmoplakin protein. Identical results were
obtained with the ZR-75 breast cancer cells (Fig. 3b).
Thus, the progestin-induced increased in desmoplakin
protein was due to increased mRNA synthesis, and this
effect could be blocked by EGF. Similar to T47D and
ZR75 cells, progestin also induced desmoplakin protein
expression in MCF-7 cells. However, under these
conditions EGF was unable to suppress the induction by
progestin of desmoplakin protein in the latter cell line
(Fig. 3c). The inability of EGF to suppress induction by
progestin of desmoplakin in MCF-7 cells was not due to
absence of an intact EGF receptor signaling pathway
because incubation of cells with 10 nmol/l EGF resulted in
activation of extracellular signal-regulated protein kinase
(ERK)1/2 within 5 min, as assessed by Western blot
analysis with phospho-ERK1/2 antibodies (data not shown).
Discussion
Our findings, gained after 48 hours of exposure to
progestin, are consistent with most clinical observations of
inhibition by progestin of cellular proliferation in progestin
receptor-positive breast tumors. Cell density, and both the
concentration and composition of the serum may be major
factors influencing progestin action in cell culture. The
conditions of cell culture described in the present study
are more similar to those of breast tumors in situ. Under
the latter circumstances, cells grow in high densities and
are richly supplied with nutrients.
Several laboratories observed a degree of reversal of the
effects of progestin on cell proliferation by EGF [11–14].
Some evidence implicates EGF and/or related peptides,
including transforming growth factor-α, not only in the
overall control of proliferation in human breast cancer cells
but also specifically in the response to progestins [12].
In these studies, a progestin upregulated gene, desmo-
plakin, was identified in three independent experiments.
The expression of desmoplakin mRNA and protein




Regulation of desmoplakin expression in breast cancer cell lines by R5020 and epidermal growth factor (EGF). (a) T47D cells were plated in RPMI
media containing 5% stripped serum. (b) ZR-75 and (c) MCF-7 cells were plated in Dulbecco’s modified Eagle medium (DMEM) containing 5%
stripped serum. Cells were incubated with vehicle, R5020, EGF, or R5020 plus EGF for 48 hours before preparation of total cellular extract for
Western blot analysis with antibody to desmoplakin or β-actin. The graphs indicate the fold difference of desmoplakin expression compared with
vehicle (set at a value of 1) following measurement of Western blot signal intensity by Kodak Image Station 440CF and 1D Image Analysis
software. In each independent experiment, duplicate samples for each treatment condition were normalized to the β-actin levels. The experiment
was repeated two times and the mean values from these experiments ± SEM are reported. Representative Western blots for desmoplakin and
β-actin levels in each cell line are shown below the graphs. *P < 0.05 versus control (by one-way analysis of variance).decreased in those cells incubated with EGF. This would
appear to be a general effect because it was also noted in
a second breast cancer cell line (ZR-75). Confounding our
observation was the inability of EGF to suppress induction
by progestin of desmoplakin in MCF-7 cells. This may be a
cell line specific effect or it merely reflect the varying
degree of differentiation between the cell lines and/or
passage number, or some other unknown reason. Thus, the
ability of EGF to suppress induction of desmoplakin by
progestin is a general but not universal effect. The
differential effect of EGF on desmoplakin induction in these
cell lines should provide appropriate models to dissect the
molecular mechanisms for crosstalk between the EGF and
progesterone receptor signaling pathways. Kester and
coworkers [15] found that desmoplakin was induced in
T47D cells by progestin in the absence of additional
hormones. Those investigators also noted that basic fibro-
blastic growth factor had no effect, and that induction of
desmoplakin mRNA was a slow process, taking 24 hours of
exposure to progestin to be measurable. A maximal effect
was noted after 2 days of exposure to progestin. Our
findings support the notion that EGF and progestin may
have opposing effects on differentiation of T47D cells.
Desmoplakin I and II are alternatively spliced products of
the same gene [16,17]. Desmoplakins are highly related
phosphoproteins and are the most abundant constituents
of the desmosomal plaque [18–22]. Synthesis of the
desmoplakins is a characteristic of certain routes of
differentiation, especially of epithelia, in which the appear-
ance of desmosomes correlates with the concomitant
expression of cytokeratin filaments that attach to them
[23]. A decrease in the amount of desmoplakin may cause
abnormal assembly of desmosomes, which results in
differences in the adhesive properties of their junctions. It
is widely believed that cell division is accompanied by a
reduction in cellular adhesives. Therefore, reduction in
cellular adhesives may lead to a greater tendency for cells
to be released from the primary tumor [24]. The expres-
sion of desmoplakin (a marker for epithelial differentiation)
along with other epithelial markers in mammary carcinoma
cell lines has been negatively correlated with invasion and
positively correlated with the differentiation state [25].
The study of desmoplakin expression in a series of rat
bladder epithelial cell lines of varying metastatic potential
suggests that abnormalities of desmoplakin expression
may contribute to tumorigenicity and invasion in bladder
carcinoma [26]. In a study of oral squamous cell carcinoma,
a negative correlation between desmoplakin staining and
loss of differentiation of the primary tumor and degree of
invasion was reported [27]. Davies and coworkers [28]
reported that loss of desmoplakin might be of potential
importance in the progression of breast cancer in vivo
from normal tissue to ductal carcinoma in situ, and from
well differentiated to poorly differentiated large tumors.
They concluded that loss of desmoplakin in breast cancer
is likely to be important in the progression and metastasis
of breast cancer in vivo.
Our study compliments recent work conducted by Lin and
coworkers [29,30], who isolated the activities of proges-
terone from the influence of estrogen. To do this they
transfected PR A/B in estrogen receptor- and proges-
terone receptor-negative MDA-MB-231 cells. Surprisingly,
they found that progesterone, acting via its receptor,
enhanced focal adhesion in transfected cells. Further-
more, they were able to demonstrate isolated proges-
tational effects on target proteins. Both the focal adhesion
protein paxillin and the focal adhesion kinase had increased
tyrosine phosphorylation under the influence of proges-
terone. Finally, Lin and coworkers noted that the induction
of focal adhesion was dependent upon the activity of the
adhesion protein β1 integrin.
However, somewhat confounding the β1 integrin story, Dai
and coworkers [31] transfected progesterone receptor into
endometrial carcinoma cells and demonstrated a decline in
β1 integrin under progestin influence. Certainly, further
analysis is warranted, but these studies demonstrate a new
and direct biologic effect of progesterone, namely cell
adhesion. Our work compliments this in that we have demon-
strated the induction of an adhesion protein under progestin
control and suppression of this effect by EGF. Of consider-
able theoretical interest is our observation of a mitogen, in
this instance EGF, having a direct impact on a steroid
sensitive cascade, which is the converse of the notion of a
progestin affecting the EGF dependent process [32].
Although we have not identified the relevant dependent
signal transduction cascades, a direct effect of
progesterone on EGF dependent pathways at the level of
ERK1/2 kinase, SAPK/JNK kinase and STAT (signal
transducers and activators of transcription) has been
demonstrated by Lange and coworkers [33] and Richer
colleagues [34]. This work described crosstalk of mitogen
and steroid signal transduction pathways. These pathways
may or may not terminate in focal adhesion although this
would certainly be of interest for future studies.
The upregulation of desmoplakin expression by progestin
may explain the partial role played by progestin in suppress-
ing tumor growth and spread during some breast cancer
therapy regimens. Upregulation of desmoplakin expression
may be associated with a progestational effect on differen-
tiation. Downregulation of desmoplakin under a dual
progestin–EGF balance may relate to invasion and meta-
stasis, thus suggesting a potential role for EGF in metastasis.
Conclusion
Desmoplakin may well serve as a useful marker for further
studies on the mechanism of crosstalk between EGF and
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R244progestin dependent pathways. Our findings suggest that
progesterone and EGF may play opposing roles in
metastasis, and suggest that desmoplakin may be a useful
biomarker for mechanistic studies designed to analyze the
crosstalk between EGF and progestin-dependent events.
Desmoplakin could also prove to be a useful marker for
further work on adhesion and metastasis. Thus, our work
may help to bridge the fields of metastasis, differentiation,
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